MELBOURNE, Australia, March 17 /PRNewswire/ --
- New Executives Appointed in Senior, Global Roles
- QuoNova Accelerating Compound Development Towards Commercialization
QuoNova LLC, which is developing multiple classes of safe and efficacious anti-virulence agents in the global fight against bacterial infection and damage caused by microbial biofilms, has appointed three new senior executives in global roles to support its next phase of growth.
QuoNova's is developing and commercializing its proprietary Quorum Sensing Blocker ("QSB") platform as part of a strategy to introduce a disruptive paradigm of "smart microbial control". QuoNova, which is 88.7% owned by XL TechGroup, Inc. (AIM: XLT), is targeting multiple multi-billion dollar markets including therapeutics, medical devices, consumer care, agriculture and several industrial applications.
Michael Rochelle has joined QuoNova as VP Strategic Marketing & Business Development. He has over 20 years of commercial experience in biopharmaceuticals, clinical laboratory and consulting. Most recently, Michael was Vice President at Nabi Pharmaceuticals, serving in a variety of roles including strategic planning and business development. He led the acquisition at Nabi of the product PhosLo(R) from Braintree Laboratories, a $100 million deal. Michael's background includes business development roles with International Clinical Laboratories, SmithKline Beecham Laboratories and Integrated Genetics/Genzyme Corporation. He has a BA in Chemistry from Assumption College in Worcester, Massachusetts and an MBA from Bryant University, in Smithfield, Rhode Island.
Jim Walls is the new VP Product Development for QuoNova. He has over 25
years of medical device product development experience, 15 years of which
were dedicated to reducing hospital acquired medical device infections. He
has held VP of R&D positions for Kendall Healthcare (now Covidien, LLC) and
C.R. Bard, Inc. Most recently he
|SOURCE QuoNova LLC|
Copyright©2008 PR Newswire.
All rights reserved